Barclays analyst Emily Field lowered the firm’s price target on Roche to CHF 260 from CHF 270 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
- Roche announces EMBARK trial in DMD did not reach primary endpoint
- Roche price target lowered to CHF 280 from CHF 290 at Morgan Stanley
- Genentech announces FDA approval for Vabysmo
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Questions or Comments about the article? Write to editor@tipranks.com